# This Page Is Inserted by IFW Operations and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ALCEIVED

AUS 1 4 2002

CENTER 1600/2000

In re Application of:

Vickie S. Thompson et al.

Serial No.: 10/017,577

Filed: 12/14/01

For: RAPID CLASSIFICATION OF BIOLOGICAL COMPONENTS

Examiner: Not assigned

Group Art Unit: Not assigned

**Attorney Docket No.: LIT-PI-372** 

#### CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

08/07/02 Date of Deposit

Signature of registered traditioner or other terson having reasonable bakis to expect mailing to occur on date of deposit shown pursuant to 37 C.F.R. '1.8(a)(1)(ii)

Mandy Landon
Typed/printed name of person whose signature is contained above

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08A be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56 (b) exists.

Applicants offer to supply any explanation or discussion of the documents which the Examiner feels is necessary or desirable and which is requested.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits.

Respectfully submitted,

Stephen R. Christian Registration No. 32,687

Attorney for Applicants P.O. Box 1625

Idaho Falls, Idaho 83415-3899

(208) 526-9140

(208) 526-8339 (FAX)

\_

**Enclosures:** 

Date: 7 AUGUST 2002

Form PTO-1449 or PTO/SB/08A

Copy of documents cited

act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduck

Attorney Docket Number

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

Sheet

AUA

Complet if Known **Application Number** 10/017,577 Filing Date 12/14/2001 First Named Inventor Vickie S. Thompson, et al. **Group Art Unit** 1645 **Examiner Name** Unknown

(use as many sheets as necessary)

LIT-PI-372

3 5005	کو عر			Approved for u	PTO/SB/08A (10-11) see through 10/31/2002. OMB 0651-0031
	טֿ		U.S. PATENT I	DOCUMENTS	in
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
	No.1	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear
	AA	us-4,542,104	9/18/1985	Phycobiliprotein Fluorescent Conjugates	600
<del></del>	l	00-1,5 12,10 1			)/2

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	0.11	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	Cite No. <sup>1</sup>	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document		T <sup>6</sup>
	AB	WO 99/38985	1/27/99	Amgen, Inc.		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	AC	A. M. Francoeur et al., 136 J. Immunol 1648 (1986)	
	AD	S. Cabilly, Combinatorial Peptide Library Protocols (Humana Press, pp. 129-154, 1997	
	AE	G. M. Santangelo et al., Cloning of Open Reading Frames and Promoters from the Saccharomyces Cerevisiae Genome: Construction of Genomic Libraries of Random Small Fragments, 46 Gene 181-186 (1986)	
	AF	S.S. Wong, Chemistry of Protein Conjugation and Cross-Linking (CRC Press, entire book, 1991)	
	AG	N. E. Good & S. Izawa, Hydrogen Ion Buffers, 24 Methods Enzymology 53-68 (1972)	
	АН	D. M. Kemeny & S. J. Challacombe, ELISA and Other Solid Phase Immunoassays (1988)	
	Al	R. C. Boguslaski et al., Clinical Immunochemistry: Principles of Methods and Applications (1984)	
·	AJ	D. P. Stites et al, Basic and Clinical Immunology (1994)	
	AK	I. Hemmila, Fluoroimmunoassays and Immunofluorometric Assays, 31 Clin. Chem. 359 (1985);	
	AL	W. Schramm, et al., Drugs of Abuse in Saliva: A Review, 16 J. Anal. Toxicology 1-9 (1992)	
	АМ	E. J. Cone, Saliva Testing for Drugs of Abuse, 694 Ann. N. Y. Acad. Sci. 91-127 (1995)	<u> </u>

Substitute for form 1449A/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Kn wn

Application Number 10/017,577

Filing Date 12/14/2001

First Named Inventor Vickie S. Thompson, et al.

Group Art Unit 1645

Examiner Name Unknown

Attorney Docket Number LIT-PI-372

(use as many sheets as necessary)

of 2

Occe.	<u> </u>	of 2 Autority booker rained.	
002 July	AN	D. A. Kidwell et al, Testing for drugs of abuse in saliva and sweat, 713 J. Chrom. B 111-135 (1998)	
Erina Cr	AO	V. S. Thompson et al., Antibody profiling as an identification tool for forensic samples, 3576 Investigation and Forensic Science Technologies 52-59 (1999)	
	AP	S. B Karch, Drug Abuse Handbook (CRC Press, 1998)	
	AQ	L. D. Bowers, Athletic Drug Testing, 17 Sports Pharmacology 299-318 (1998)	∷\ /2900
	AR	Parry, Tests for HIV and hepatitis viruses, 694 Annals N. Y Acad. Sci. 221 (1993)	
	AS	M. Peat & A.E. Davis, Drug Abuse Handbook (CRC Press, Boca Raton, Fla. 1998)	
	АТ	Larry D. Bowers, Ph.D. Athletic Drug Testing, Sport Pharmacology, pp.299-319	
	AU	Cambridge Healthtech Institute's Fourth Annual, DNA Forensics (Brochure)	
	AV	Jeffrey Baird, Forensic DNA in the Trial Court 19909-1992: A Brief History, pp. 61-75	
	AW	Controversy Over Forensic DNA Analysis, Science in the Courtroom, QC Researcher, pp. 924-925	
	AX	John McCabe, DNA Fingerprinting: The Failings of Frye, pp. 455-481	
		·	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE aperwork Reduction act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/017,577 Application Numb r TRANSMITTAL 12/14/2001 **Filing Date** 3 2002 Vickie Thompson, et al **FORM First Named Inventor** МВ 1645 (to be used for all correspondence after initial filing) Group Art Unit (A)VZ Unknown **Examiner Name** LIT-PI-372 Total Number of Pages in This Submission Attorney Docket Number **ENCLOSURES** (check all that apply) After Allowance Communication **Assignment Papers** Fee Transmittal Form (for an Application) to Group Appeal Communication to Board Fee Attached Drawing(s) of Appeals and Interferences Appeal Communication to Group Licensing-related Papers Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition After Final **Proprietary Information** Petition to Convert to a Affidavits/declaration(s) **Provisional Application** Status Letter Power of Attorney, Revocation Change of Correspondence Address Other Enclosure(s) (please identify below) **Extension of Time Request** Terminal Disclaimer **Express Abandonment Request** Request for Refund Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Remarks Document(s) Response to Missing Parts/ Supplemental IDS with Cited Art, PTO/SBEA Form Incomplete Application Return Receipt Postcard Response to Missing Parts under 37 CFR 1.52 or 1.53

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Signature

Date

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

OR AGENT

OR OF APPLICANT, ATTORNEY, ATTOR

	CERTIFICATE OF MAILIN	NG	
I hereby certify that this corresp mail in an envelope addressed	ondence is being deposited with the United States Poto: Commissioner for Patents, Washington, DC 20231	stal Service on this date	with sufficient postage as first class
Typed or printed name	Mandy Landon		
Signature	Mandy Tandon	Date	08/07/2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.